Pipeline · Bill → Law
Step 1
Introduced
Jun 13, 2023
Step 2
Referred
Jun 16, 2023
E&C · Judiciary
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.) Specifically, the bill requires HHS to review scientific and medical evaluations relating to these product...
Timeline · 4 actions
Jun 16, 2023
Referred to the Subcommittee on Health.
Jun 13, 2023
Introduced in House
Jun 13, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 13, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.